Trimel Reports Positive CompleoTRT(TM) Patient Market Research Results

- 42% of those previously treated with a testosterone replacement therapy felt better on CompleoTRT(TM) - 70% previously treated with a testosterone replacement therapy would stay on CompleoTRT(TM) - 84% were confident in administering CompleoTRT(TM) within 2 days

Marketwired

TORONTO, ONTARIO--(Marketwire - Jan 7, 2013) - Trimel Pharmaceuticals Corporation (TRL.TO) (the "Company" or "Trimel") today announced positive results from a recently completed market research study that surveyed patients who participated in the CompleoTRT™ Phase III efficacy study. 

The quantitative study conducted in the United States surveyed 99 patients who had a minimum of 90 days of CompleoTRT™ treatment, 50 of whom were previously treated with another testosterone replacement therapy. Respondents participated on a voluntary basis, with the survey administered by the contract research organization responsible for conducting the Phase III trial. Patients were asked questions specific to their experience with administering CompleoTRT™ on a daily basis and were asked to assess, if applicable, how their experience with CompleoTRT™ compared to that of their previous testosterone therapies. 

For those patients who had previous experience with other testosterone replacement therapies, 42% indicated that they felt better on CompleoTRT™ as compared to their previous experience, while 34% felt the same. When asked if they would use CompleoTRT™ if it were approved and available by prescription, 70% of those who were previously treated with a testosterone replacement therapy would adopt CompleoTRT™ rather than return to their previous therapy.

Finally, 84% of the patients participating in the survey were confident in applying CompleoTRT™ intranasally within 2 days of initiating therapy during the trial.

Tom Rossi, President and Chief Executive Officer, offered the following comment: "These positive findings further corroborate the feedback we received from our recently announced physician independent market research study. Physicians surveyed recognized the advantages of CompleoTRT™ and indicated a willingness to prescribe it to a good percentage of their Low T patients. As well, most patients who participated in the patient market research study indicated they would prefer it over other products they have used in the past. These two findings, together, provide further support for the tremendous opportunity that CompleoTRT™ could represent in a rapidly growing testosterone market starved for innovation."

About CompleoTRT™

CompleoTRT™ is designed to represent a significant advancement in the treatment of male hypogonadism, or low testosterone. CompleoTRT™''s unique delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form of a bioadhesive intranasal gel.

CompleoTRT™''s intranasal no-touch delivery system is designed to avoid the risk of accidental transfer (secondary transference) of testosterone to spouses or other family members, thus offering unique patient benefits and improved safety as compared to other currently marketed products indicated to treat "Low T". Since Trimel took over development in May 2009, CompleoTRT™ has been optimized in an effort to meet FDA regulatory requirements, including the development of a no-touch applicator device that is designed to ensure that CompleoTRT™ is dosed accurately and discretely.

On December 6, 2012, Trimel announced that its Phase III pivotal clinical trial for CompleoTRT™ had met its primary efficacy endpoints. Based on these clinical results, Trimel will continue the process of completing its New Drug Application for filing with the FDA.

About Trimel

Trimel Pharmaceuticals Corporation (TRL.TO) - Developing medications for Men''s Health, Female Sexual Dysfunction and Respiratory Therapy . Trimel is developing multiple product opportunities, including CompleoTRT™, a bioadhesive intranasal testosterone gel that has completed Phase III clinical efficacy testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Tom Rossi, President and Chief Executive Officer at (905) 817-8194 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

This press release contains forward-looking information. This forward-looking information is not based on historical facts but rather on the expectations of the Company''s management regarding the future growth of the Company and its respective results of operations, performance and business prospects and opportunities. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. This press release uses words such as "believe", "expect", "would", "will", "expects", "anticipates", "intends", "estimates", or similar expressions to identify forward-looking information. Such forward-looking information reflects the current beliefs of the Company''s management based on information currently available to them.

Forward-looking information included in this press release is based, in part, on factors and assumptions that may change, thus causing actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information. Such factors and assumptions include that: the Company will achieve, sustain or increase profitability, and will be able to fund its operations with existing capital, and/or it will be able to raise additional capital to fund operations; the Company will be able to attract and retain key personnel; the Company will be able to acquire any necessary technology or businesses and effectively integrate such acquisitions; the Company will be successful in developing and clinically testing products under development; the Company will be successful in obtaining all necessary approvals for commercialization of its products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; the results of continuing and future safety and efficacy studies by industry and government agencies relating to the Company''s products will be favourable; the Company''s products will not be adversely impacted by competitive products and pricing; raw materials and finished products necessary for the Company''s products will be available; the Company will be able to maintain and enforce the protection afforded by any patents or other intellectual property rights; the Company''s products will be successfully licensed to third parties to market and distribute such products on favourable terms; the Company''s key strategic alliances, out licensing and partnering arrangements, now and in the future, will remain in place and in force; the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiaries will remain constant and the Company will not become subject to any material legal proceedings. The Company cautions that the foregoing list of assumptions is not exhaustive.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Risks related to forward-looking statements include those risks described in the Company''s Annual Information Form dated March 9, 2012 under the heading "Risk Factors" and updated by the Company''s short form prospectus dated July 11, 2012 under the headings "Forward-Looking Statements" and "Risk Factors". Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking information in this press release, and, accordingly, investors should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made and the Company undertakes no obligation to update any forward-looking information to reflect the occurrence of unanticipated events, except as required by law. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for management of the Company to predict all of such factors, changes in such factors and to assess in advance the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this press release.

Contact:
Trimel Pharmaceuticals Corporation
Tom Rossi
President and Chief Executive Officer
(905) 817-8194
Trimel Pharmaceuticals Corporation
Kenneth Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com

View Comments (0)